Mintz advised the underwriters in connection with Benitec Biopharma’s follow-on public offering of 5,930,000 shares of common stock at a public offering price of $13.50 per share, and the placement agents in the concurrent registered direct offering of 1,481,481 shares of common stock at an offering price of $13.50 per share. The aggregate gross proceeds to Benitec Biopharma from these offerings were approximately $100 million before deducting underwriting discounts and commissions, placement agent fees, and other offering expenses. In addition, Benitec Biopharma granted the underwriters a 30-day option to purchase up to an additional 889,500 shares of its common stock at the public offering price.

Leerink Partners, TD Cowen and Evercore ISI acted as bookrunning managers for the underwritten public offering and as placement agents for the concurrent registered direct offering. 

The Mintz capital markets team included William C. Hicks, John Rudy, Nishant Dharia, Allyson Wilkinson, Jessica Zhang, and Kate McLeod. Joanne Hawana provided regulatory advice, and Serge Banini and Sam Pilicer provided intellectual property advice. Members of the Mintz team are based in the Boston, New York, Washington, DC, and San Francisco offices.